June 28, 2024 11:30 AM EDTUpdated 04:37 PM

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Lei Lei Wu

News Reporter

Johnson & Johnson’s experimental autoimmune treatment lowered the impact of myasthenia gravis on daily life compared to placebo in antibody-positive patients in a late-stage study …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

Immunology biotech Alumis secures $250M in shrunken IPO

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Lei Lei Wu

News Reporter

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

Im­munol­o­gy biotech Alu­mis se­cures $250M in shrunk­en IPO

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Why the Supreme Court's overrule of Chevron has major implications for the FDA

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

Immunology biotech Alumis secures $250M in shrunken IPO